University Hospital of Navarra
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sangro, Bruno
EMERALD-1, NCT03778957 / 2018-002134-20: A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Hourglass Jul 2023 - Dec 2023 : Data from EMERALD-1 trial for HCC
Active, not recruiting
3
724
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Bevacizumab, AVASTIN, Placebo, Transarterial Chemoembolization (TACE)
AstraZeneca
Hepatocellular Carcinoma
09/23
08/26
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NEOTOMA, NCT05440864: Durvalumab and Tremelimumab in Resectable HCC

Recruiting
2
28
Europe, Canada
Tremelimumab, Durvalumab
University Health Network, Toronto, Clinica Universidad de Navarra, Universidad de Navarra, University of Milan
Hepatocellular Carcinoma
11/25
11/26
ROWAN, NCT05063565 / 2021-001907-33: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
Gómez-Espuch, Joaquín
TranspoCART19, NCT06378190 / 2022-001040-23: Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Recruiting
1/2
27
Europe
CAR-T cells therapy
Instituto de Investigación Biomédica de Salamanca, Spanish Clinical Research Network - SCReN, Fundación Canaria de Investigación Sanitaria, Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent
07/28
07/30

Download Options